CRDL – cardiol therapeutics inc. - class a common shares (US:NASDAQ)
Stock Stats
News
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis [Yahoo! Finance]
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Trends in the $6 Billion Botanical Drugs Industry, 2030: An Assessment of Emerging Growth Opportunities and Strategic Developments [Yahoo! Finance]
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Form 6-K Cardiol Therapeutics For: Nov 18
Form 6-K Cardiol Therapeutics For: Sep 30
Form SC 13G/A Cardiol Therapeutics Filed by: MMCAP International Inc. SPC
Form 6-K Cardiol Therapeutics For: Oct 22
Form 6-K Cardiol Therapeutics For: Oct 11
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.